What do the Konami code and targeting KRAS have in common?

A rock around the KRAS clock

July 12, 2022

The long and winding road to success

An emerging new and highly selective oncogenic target

June 30, 2022

An alternative perspective on TIGIT

What can we learn from IO trials in lung cancer to help us evaluate TIGIT's prospects?

June 23, 2022

Seeing the wood from the trees in early stage oncology pipelines

Exploring future IO-IO combination strategies and life cycle management

June 16, 2022

A critical review of five different targeted therapy approaches at ASCO

Where five different targeted therapies are put through their paces

June 13, 2022

The good, the bad, the plain old ugly, and the promising

There’s always a parable or two to be had at ASCO and this year was no different, especially in…

June 7, 2022

Talkin’ ’bout a Revolution

The continuous evolution of BCMA CAR-T cell therapy products and how they are doing

June 6, 2022

Trials and Tribulations

A look at early stage CAR-T cell therapies in development

June 5, 2022

ASCO22 Highlights from Day 1

When cell therapies and targeted therapies collide

June 4, 2022

Five key areas to watch out for at ASCO22

Five key areas to watch out for at ASCO22

June 1, 2022

The Forgotten Checkpoints

What can we learn from the data on inhibitory checkpoints not named PD(L)1 or TIGIT?

May 26, 2022

A high level view of the latest Target Protein Degradation data

What's the skinny on C4 Therapeutics and other TPD programs at AACR and ASCO?

May 16, 2022

Take the high road

5 abstracts to watch out for at the ASCO22 meeting in Chicago

May 2, 2022

A journey that never ends

Can NK cells help checkpoint blockade work more effectively?

April 27, 2022